Literature DB >> 7531387

Inhibition of inflammatory angiogenesis in rats by loco-regional administration of hydrocortisone and protamine.

D Foschi1, L Castoldi, F Corsi, E Radaelli, E Trabucchi.   

Abstract

We have studied the antiangiogenetic effects of hydrocortisone and protamine given intra-arterially. The cornea of male, Sprague-Dawley rats were cauterized with silver nitrate. The following treatments were given: 30 micrograms hydrocortisone topical (t.p.), b.i.d., 50 mg/kg/day intraperitoneally (i.p.) or intra-arterially (i.a.), 10 mg/kg/day protamine i.p. or i.a. Saline was administered to the control groups. In separate experiments we also evaluated the anti-inflammatory effects of hydrocortisone, i.p., on the cauterized corneas. Five days after cauterization, the animals were killed, exsanguinated and India ink was injected to show the network of neovessels. The percentage area of the cornea covered by neovessels was measured morphometrically and evaluated statistically. Hydrocortisone t.p. (-84%), i.a. (-60%) and protamine i.a. (-44%) significantly inhibited angiogenesis in the cauterized cornea. Either drugs, i.p., had any antiangiogenetic effects, but hydrocortisone significantly reduced cell infiltration of the corneas. The results suggest that locoregional administration of antiangiogenetic drugs might be clinically useful.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531387     DOI: 10.1007/bf02014298

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  16 in total

1.  The histopathology of corneal neovascularization. Inhibitor effects.

Authors:  J B Robin; L F Regis-Pacheco; R L Kash; D J Schanzlin
Journal:  Arch Ophthalmol       Date:  1985-02

2.  A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution.

Authors:  D E Ingber; J A Madri; J Folkman
Journal:  Endocrinology       Date:  1986-10       Impact factor: 4.736

3.  Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.

Authors:  T Matsubara; R Saura; K Hirohata; M Ziff
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

4.  Protamine is an inhibitor of angiogenesis.

Authors:  S Taylor; J Folkman
Journal:  Nature       Date:  1982-05-27       Impact factor: 49.962

5.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.

Authors:  D Ingber; T Fujita; S Kishimoto; K Sudo; T Kanamaru; H Brem; J Folkman
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

6.  Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane.

Authors:  E A Woltering; R Barrie; T M O'Dorisio; D Arce; T Ure; A Cramer; D Holmes; J Robertson; J Fassler
Journal:  J Surg Res       Date:  1991-03       Impact factor: 2.192

7.  A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment.

Authors:  R Crum; S Szabo; J Folkman
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

8.  Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone.

Authors:  J Folkman; R Langer; R J Linhardt; C Haudenschild; S Taylor
Journal:  Science       Date:  1983-08-19       Impact factor: 47.728

9.  Inhibition of angiogenesis through modulation of collagen metabolism.

Authors:  D Ingber; J Folkman
Journal:  Lab Invest       Date:  1988-07       Impact factor: 5.662

10.  Mast cell heparin stimulates migration of capillary endothelial cells in vitro.

Authors:  R G Azizkhan; J C Azizkhan; B R Zetter; J Folkman
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  1 in total

1.  Hydrocortisone-induced parkin prevents dopaminergic cell death via CREB pathway in Parkinson's disease model.

Authors:  Sangwoo Ham; Yun-Il Lee; Minkyung Jo; Hyojung Kim; Hojin Kang; Areum Jo; Gum Hwa Lee; Yun Jeong Mo; Sang Chul Park; Yun Song Lee; Joo-Ho Shin; Yunjong Lee
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.